



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 168608

TO: Paul Martin
Location: 4b71 / 3c18
Tuesday, October 18, 2005
Art Unit: 1655
Phone: 571-272-3348
Serial Number: 10 / 748335

From: Jan Delaval
Location: Biotech-Chem Library
Remsen 1a51
Phone: 571-272-2504

jan.delaval@uspto.gov

Search Notes

FOR OFFICIAL USE ONLY

ACCESS DB # 168608
PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: PAUL MARTIN Examiner #: 81449 Date: 10/14/05
Art Unit: 1655 Phone Number: 2-3348 Serial Number: 10748335
Location (Bldg/Room#): _____ (Mailbox #): _____ Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Identification of Active site inhibitors of glycosyltransferase using
a generalizable high throughput screen
Inventors (please provide full names): Suzanne Walter Kahne, Daniel Kahne

Earliest Priority Date: 12/30/02

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search claim 11

fluorescein labeled UDP-GlcNAc hexose analog
↑
(N-acetylglucosamine)

used in glycosyltransferase binding assay
↑ (MUG)

displacement assay

or substrate polarization

STAFF USE ONLY

Searcher: Jan
Searcher Phone #: 22504
Searcher Location: _____
Date Searcher Picked Up: 10/18/05
Date Completed: 10/18/05
Searcher Prep & Review Time: 10
Online Time: 135

Type of Search

____ NA Sequence (#)
____ AA Sequence (#)
☒ Structure (#)
____ Bibliographic
____ Litigation
____ Fulltext
____ Other

Vendors and cost where applicable

☒ STN _____ Dialog
____ Questel/Orbit _____ Lexis/Nexis
____ Westlaw _____ WWW/Internet
____ In-house sequence systems
____ Commercial _____ Oligomer _____ Score/Length
____ Interference _____ SPDI _____ Encode/Transl
____ Other (specify) _____



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact:*

Mary Hale, Information Branch Supervisor
308-4258, CM1-1E01

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 – Circ. Desk



=> d his

(FILE 'HOME' ENTERED AT 15:03:15 ON 18 OCT 2005)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 15:03:41 ON 18 OCT 2005

L1 1 S US20050142629/PN OR US2003-784335#/AP, PRN
E KAHNE D/AU
L2 117 S E3-E7
E KAHNE S/AU
L3 8 S E4, E5
E WALKER S/AU
L4 210 S E3
L5 20 S E17
E WALKER SUE/AU
L6 48 S E21
SEL RN L1

FILE 'REGISTRY' ENTERED AT 15:05:45 ON 18 OCT 2005

L7 48 S E1-E48
L8 4 S L7 AND (OC5-C6-C6 OR OC4-OC5-C6-C6-C6)/ES
L9 2 S L8 AND OC5/ES
L10 1 S L9 AND NCNC3/ES
L11 75563 S (OC5-C6-C6 OR OC4-OC5-C6-C6-C6)/ES
L12 1637 S L11 AND OC5/ES
L13 103 S L12 AND (OC4 AND NCNC3)/ES
L14 91 S L13 AND P/ELS
L15 28 S L14 AND 8/NR
L16 17 S L15 NOT S/ELS
L17 1 S L16 AND C38H38N4O23P2
L18 2 S L8 AND OC4-OC5-C6-C6-C6/ES NOT L9
L19 1 S L18 NOT N/ELS
L20 1 S 58-98-0
E N-ACT5EYLGLUCOSAMINE/CN
E N-ACETYLGLUCOSAMINE/CN
L21 1 S E3
E C38H38N4O23P2/MF

FILE 'HCAOLD' ENTERED AT 15:16:10 ON 18 OCT 2005

L22 0 S L17

FILE 'HCAPLUS' ENTERED AT 15:16:14 ON 18 OCT 2005

L23 2 S L17
L24 0 S L19 AND L20 AND L21
L25 6310 S L19
L26 25115 S FLUORESCEIN?
L27 25589 S L25, L26
L28 2084 S L20
L29 16687 S UDP OR URID? (L) DIHYDROGEN (L) ?PHOSPH?
L30 16657 S UDP OR URID? (L) ?PHOSPH? (L) GLUCORON?
L31 4962 S URID? (L) DIPHOSPH?
L32 40 S L27 AND L28-L31
L33 5969 S L21
L34 25484 S ?ACETYLGLUCOSAMIN? OR ?ACETY? (L) ?GLUCOSAMIN?
L35 9 S L32 AND L33, L34

FILE 'REGISTRY' ENTERED AT 15:25:37 ON 18 OCT 2005

L36 1 S 528-04-1

FILE 'HCAPLUS' ENTERED AT 15:25:47 ON 18 OCT 2005

L37 1276 S L36
L38 7 S L37 AND L27
L39 1 S L38 NOT L35
SEL DN AN L35 2 4 8 9
L40 4 S E1-E12 AND L35
L41 4 S L37 AND L40
L42 5 S L23,L41
L43 2 S L1-L6 AND L42
L44 5 S L42,L43
L45 2 S L44 AND GLCNAC
L46 5 S L44,L45

FILE 'USPATFULL, USPAT2' ENTERED AT 15:29:27 ON 18 OCT 2005

L47 1 S L17

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 15:29:46 ON 18 OCT 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:29:46 ON 18 OCT 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l47 bib abs hitstr

L47 ANSWER 1 OF 1 USPATFULL on STN

AN 2005:165205 USPATFULL

TI Identification of active-site inhibitors of glycosyltransferases using a generalizable high-throughput screen

IN Kahne, Suzanne Walker, Princeton, NJ, UNITED STATES

Kahne, Daniel, Princeton, NJ, UNITED STATES

PI US 2005142629 A1 20050630

AI US 2003-748335 A1 20031230 (10)

DT Utility

FS APPLICATION

LREP Patrick H. Higgins, Mathews, Collins, Shepherd & McKay, Suite 306, 100 Thanet Circle, Princeton, NJ, 08540, US

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 1398

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is described for identifying a compound that modulates the ability of a glycosyltransferase to bind a substrate comprising combining a glycosyltransferase, a labeled substrate, and a compound, in a reaction vessel, under conditions known to be suitable for the glycosyltransferase to bind the labeled substrate, measuring an amount of labeled substrate bound to the glycosyltransferase, and comparing the amount to a standardized amount to identify a relative increase or decrease in substrate bound glycosyltransferase, thereby identifying a compound that modulates the ability of the glycosyltransferase to bind the substrate. A composition comprising an effective amount of a compound of Formula I (the substituents of which are described herein), or a stereoisomer, or pharmaceutically acceptable salt thereof, that inhibits the ability of a glycosyltransferase to bind a substrate, in a pharmaceutically acceptable carrier is provided ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 608143-47-1P

(glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

RN 608143-47-1 USPATFULL

CN Uridine 5'-(trihydrogen diphosphate), P'-[2-deoxy-2-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)carbonyl]amino]acetyl]amino]-α-D-glucopyranosyl] ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 15:29:53 ON 18 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Oct 2005 VOL 143 ISS 17

FILE LAST UPDATED: 17 Oct 2005 (20051017/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d all hitstr tot

jan delaval - 18 october 2005

L59 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:572457 HCAPLUS
 DN 143:90985
 ED Entered STN: 01 Jul 2005
 TI Identification of active-site inhibitors of glycosyltransferases using a
 generalizable high-throughput screen
 IN Kahne, Suzanne Walker; Kahne, Daniel
 PA USA
 SO U.S. Pat. Appl. Publ., 26 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM C12Q001-48
 INCL 435015000
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 7, 33, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005142629	A1	20050630	US 2003-748335	20031230 <--
PRAI	US 2003-748335		20031230		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2005142629	ICM	C12Q001-48
	INCL	435015000
US 2005142629	NCL	435/015.000

OS MARPAT 143:90985

AB A method is described for identifying a compound that modulates the ability of a glycosyltransferase to bind a substrate, comprising combining a glycosyltransferase, a labeled substrate, and a compound, in a reaction vessel, under conditions known to be suitable for the glycosyltransferase to bind the labeled substrate, measuring an amount of labeled substrate bound to the glycosyltransferase, and comparing the amount to a standardized amount to identify a relative increase or decrease in substrate bound glycosyltransferase, thereby identifying a compound that modulates the ability of the glycosyltransferase to bind the substrate. A composition comprising an effective amount of a compound that inhibits the ability of a glycosyltransferase to bind a substrate, in a pharmaceutically acceptable carrier, is also provided. The invention further provides methods for controlling the growth of bacteria using the compds. of the invention. Compds. of the invention include e.g. 5-(4-tert-butylbenzylidene)-3-(4-methylpiperidin-1-ylmethyl)-2-thioxothiazolidin-4-one. Preparation of a **fluoresceinated UDP-N-acetylglucosamine** analog is included.

ST high throughput screen glycosyl transferase inhibitor antibacterial; thioxothiazolidinone deriv glycosyl transferase inhibitor antibacterial; **UDP acetylglucosamine** analog prepn glycosyl transferase inhibitor screening

IT Crystal structure
 (MurG-bound **UDP-GlcNAc**; glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT Peptidoglycans
 RL: BSU (Biological study, unclassified); BIOL (Biological study).
 (bacterial peptidoglycan synthesis; glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT Infection
 (bacterial; glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT Antibacterial agents
 Chromophores
 Drug screening
 Dyes
 Fluorescent substances
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT Enzymes, biological studies
 Radionuclides, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT 58-98-0, UDP, biological studies 146-91-8, GDP
 491-97-4, TDP 528-04-1 9023-27-2, Gene MurA enzyme
 9033-07-2, Glycosyltransferase 60976-26-3, MurG glycosyltransferase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT 58-64-0, ADP, biological studies 58-97-9, UMP, biological studies 2321-07-5, **Fluorescein**
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT 608143-47-1P
 RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT 292168-98-0 292168-98-0D, stereoisomers and salts 292169-21-2
 292169-21-2D, stereoisomers and salts 292170-21-9 292170-21-9D,
 stereoisomers and salts 301305-25-9 301305-25-9D, stereoisomers and
 salts 310421-16-0 310421-16-0D, stereoisomers and salts 312501-65-8
 312501-65-8D, stereoisomers and salts 312537-70-5 312537-70-5D,
 stereoisomers and salts 313239-10-0 313239-10-0D, stereoisomers and
 salts 315235-61-1 315235-61-1D, stereoisomers and salts 321556-92-7
 321556-92-7D, stereoisomers and salts 328247-46-7 328247-46-7D,
 stereoisomers and salts 329200-08-0 329200-08-0D, stereoisomers and
 salts 330578-01-3 330578-01-3D, stereoisomers and salts 330842-29-0
 330842-29-0D, stereoisomers and salts 330843-83-9 330843-83-9D,
 stereoisomers and salts 330844-25-2 330844-25-2D, stereoisomers and
 salts 330845-76-6 330845-76-6D, stereoisomers and salts 340017-89-2
 340017-89-2D, stereoisomers and salts 340213-82-3 340213-82-3D,
 stereoisomers and salts 340309-84-4 340309-84-4D, stereoisomers and
 salts 347385-19-7 347385-19-7D, stereoisomers and salts 347387-81-9
 347387-81-9D, stereoisomers and salts 347389-31-5 347389-31-5D,
 stereoisomers and salts 350693-04-8 350693-04-8D, stereoisomers and
 salts 381708-09-4 381708-09-4D, stereoisomers and salts 745037-23-4
 745037-23-4D, stereoisomers and salts 745037-24-5 745037-24-5D,
 stereoisomers and salts 745037-25-6 745037-25-6D, stereoisomers and
 salts 856570-62-2 856570-62-2D, stereoisomers and salts 856570-63-3
 856570-63-3D, stereoisomers and salts 856570-64-4 856570-64-4D,
 stereoisomers and salts
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT 19286-16-9 108549-23-1 117548-22-8
 RL: RCT (Reactant); RACT (Reactant or reagent)


(glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT 856570-65-5P 856570-66-6P **856570-67-7P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

IT **58-98-0, UDP**, biological studies **528-04-1**
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)


RN 58-98-0 HCAPLUS
 CN Uridine 5'-(trihydrogen diphosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528-04-1 HCAPLUS
 CN Uridine 5'-(trihydrogen diphosphate), P'-[2-(acetylamino)-2-deoxy- α -D-glucopyranosyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT **58-97-9, UMP**, biological studies **2321-07-5, Fluorescein**
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)


RN 58-97-9 HCAPLUS
 CN 5'-Uridylic acid (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 2321-07-5 HCAPLUS

CN Spiro[isobenzofuran-1(3H), 9'-[9H]xanthen]-3-one, 3',6'-dihydroxy- (9CI)
(CA INDEX NAME)




IT 608143-47-1P

RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

RN 608143-47-1 HCAPLUS

CN Uridine 5'-(trihydrogen diphosphate), P'-[2-deoxy-2-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H), 9'-[9H]xanthen]-5-yl)carbonyl]amino]acetyl]amino]-α-D-glucopyranosyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 117548-22-8

RL: RCT (Reactant); RACT (Reactant or reagent)
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

RN 117548-22-8 HCAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5(or 6)-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



IT 856570-67-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (glycosyltransferases inhibitor screening and use for controlling growth of bacteria)

RN 856570-67-7 HCAPLUS

CN α -D-Glucopyranose, 2-deoxy-2-[[[[(3',6'-dihydroxy-3-

oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)carbonyl]amino]acetyl]amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L59 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:354961 HCAPLUS
 DN 140:370523
 ED Entered STN: 30 Apr 2004
 TI Synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into the protein
 IN Schultz, Peter G.; Wang, Lei; Zhang, Zhiwen
 PA The Scripps Research Institute, USA
 SO PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07K
 CC 6-3 (General Biochemistry)
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004035605	A2	20040429	WO 2003-US32870	20031015
	WO 2004035605	A3	20050512		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2500653	AA	20040429	CA 2003-2500653	20031015
	US 2004138106	A1	20040715	US 2003-686944	20031015
	US 6927042	B2	20050809		
	EP 1558747	A2	20050803	EP 2003-777634	20031015
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 2005181471	A1	20050818	US 2005-94677	20050329
	US 2005186656	A1	20050825	US 2005-93798	20050329
	US 2005186657	A1	20050825	US 2005-94676	20050329

	US 2005209133	A1	20050922	US 2005-93797	20050329
PRAI	US 2002-419265P	P	20021016		
	US 2002-420990P	P	20021023		
	US 2003-441450P	P	20030116		
	US 2003-686944	A3	20031015		
	WO 2003-US32870	W	20031015		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2004035605	ICM	C07K
WO 2004035605	ECLA	C12P021/00B
CA 2500653	ECLA	C12P021/00B
US 2004138106	NCL	514/008.000
EP 1558747	ECLA	C12P021/00B
US 2005181471	NCL	435/068.100; 530/395.000; 530/409.000
US 2005186656	NCL	435/068.100; 435/193.000; 530/395.000
US 2005186657	NCL	435/068.100; 435/193.000; 530/395.000
US 2005209133	NCL	514/008.000; 530/322.000

AB Methods for glycosidating proteins to give novel positions and patterns of glycosidation are described. One method involves incorporating an unnatural amino acid containing a reactive group into a protein and attaching one or more saccharide moieties to the unnatural amino acid. Another method involves incorporating an unnatural amino acid that includes a saccharide moiety into a protein. Proteins made by both methods can be further modified with addnl. sugars. Methods of introducing ketoamino acids into proteins during protein synthesis by means of tRNA variants charged with the amino acid and aminoacyl-tRNA synthetase derivs. capable of charging the tRNAs with ketoaminoacids are described. The tRNA recognizes a codon such as a stop codon, a rare codon, or a tetranucleotide or longer sequence that is rare in the gene of interest. A mutant Methanococcus jannaschii tyrosyl tRNA synthetase that could suppress amber mutations in a chloramphenicol acetyltransferase gene was selected and screened for growth on chloramphenicol in the presence p-acetyl-L-phenylalanine. Translation of genes containing amber mutations in the presence of this synthetase resulted in the introduction of the keto amino acid at the specific sites in the presence of an amer suppressor tRNA. The protein could be modified with **fluorescein** hydrazide and biotin hydrazide at the corresponding sites.

ST protein glycosidation translation amino acid analog reactive group; ketoamino acid protein synthesis tRNA synthetase variant; amino acid analog protein synthesis tRNA synthetase variant

IT tRNA

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(amber suppressor, incorporation of amino acid analogs using; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)

IT Codons

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(amber, suppression of, incorporation of amino acid analogs using; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)

IT Nucleophiles

(amino acid analogs as, for glycosidation; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)

IT Glycosides

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(amino acid, incorporation into proteins of; synthetic glycosylation of

- proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(analogs, incorporation into proteins of; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT Escherichia coli
(expression host; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT DNA sequences
(for tyrosyl tRNA synthetase variants of Methanococcus jannaschii; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(glycosides, incorporation into proteins of; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT Translation, genetic
(incorporation of unnatural amino acids in; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT Protein engineering
(of aminoacyl-tRNA synthetases; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT Glycosylation
(of proteins; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT Genetic engineering
Molecular cloning
(synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT Glycoproteins
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT tRNA
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(tyrosine-specific, variants, for introduction of amino acid analogs; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT Methanococcus jannaschii
(tyrosyl tRNA synthetase of; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 60063-85-6, Galacturonyltransferase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(Galacturonyltransferase, for glycosidation of proteins; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 9054-44-8, N-Acetylgalactosaminyltransferase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

- (acetylgalactosaminyltransferase, for glycosidation of proteins; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 684302-79-2 684302-80-5 684302-81-6 684302-82-7 684302-83-8
684302-84-9
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 61652-90-2DP, protein conjugates 70858-45-6DP, protein conjugates
71369-21-6DP, protein conjugates 81034-76-6DP, protein conjugates
84808-02-6DP, protein conjugates
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(enzymic preparation in protein glycosidation; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 9023-45-4D, Tyrosyl tRNA synthetase, variants
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(for charging tRNA with amino acid analogs; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 57534-80-2, Glucuronic acid transferase 192588-73-1, Glycoprotein glucuronyltransferase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(for glycosidation of proteins; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 56626-18-7, Fucosyltransferase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(fucosyltransferase, for glycosidation of proteins; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 9031-68-9, Galactosyltransferase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(galactosyltransferase, for glycosidation of proteins; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 9031-48-5, Glucosyltransferase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(glucosyltransferase, for glycosidation of proteins; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 7512-17-6, N-Acetylglucosamine
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(glycosidation of proteins at; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 528-04-1 2956-16-3, UDP-galactose 3123-67-9, GDP-mannose .9054-94-8, β -1,4-Galactosyltransferase 83744-93-8
135622-87-6 193099-05-7 202420-38-0 334993-76-9
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

- (glycosidation of proteins using; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 17041-36-0 21008-33-3 67315-18-8 685088-58-8
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (incorporation into proteins; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 22888-49-9P
 RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (introduction into proteins of; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 9055-06-5, Mannosyltransferase
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (mannosyltransferase, for glycosidation of proteins; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 684302-85-0 684302-86-1 684302-87-2 684302-88-3
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
 (nucleotide sequence; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 66640-86-6, Biotin hydrazide 109653-47-6, Fluorescein hydrazide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (protein modification with; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 78-67-1, AIBN 122-00-9 128-08-5, N-Bromosuccinimide 1068-90-2, Diethyl acetamidomalonate 204716-07-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactions of; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 321976-25-4, Sialyltransferase
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (sialyltransferase, for glycosidation of proteins; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 56093-23-3, α -1,2 Fucosyltransferase
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (α -1,2-fucosyltransferase, glycosidation of proteins using; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 68247-53-0, α (1,3)-Fucosyltransferase
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (α -1,3-fucosyltransferase, glycosidation of proteins using; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)
- IT 111310-37-3, α (1,4)-Fucosyltransferase
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (α -1,4-fucosyltransferase, glycosidation of proteins using;

synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)

IT 7512-17-6, N-Acetylglucosamine


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(glycosidation of proteins at; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)

RN 7512-17-6 HCAPLUS

CN D-Glucose, 2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 528-04-1 2956-16-3, UDP-galactose


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(glycosidation of proteins using; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)

RN 528-04-1 HCAPLUS

CN Uridine 5'-(trihydrogen diphosphate), P'-[2-(acetylamino)-2-deoxy- α -D-glucopyranosyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 2956-16-3 HCAPLUS

CN Uridine 5'-(trihydrogen diphosphate), P'- α -D-galactopyranosyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 109653-47-6, **Fluorescein hydrazide**

RL: RCT (Reactant); RACT (Reactant or reagent)

(protein modification with; synthetic glycosylation of proteins by incorporation of unnatural amino acids with novel reactive groups into protein)

RN 109653-47-6 HCAPLUS

CN Benzoic acid, 2-(3,6-dihydroxy-9H-xanthen-9-yl)-, hydrazide (9CI) (CA INDEX NAME)



L59 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:652522 HCAPLUS

DN 139:285735

ED Entered STN: 22 Aug 2003

TI Identification of Active-Site Inhibitors of MurG Using a Generalizable, High-Throughput Glycosyltransferase Screen

AU Helm, Jeremiah S.; Hu, Yanan; Chen, Lan; Gross, Ben; **Walker, Suzanne**

CS Department of Chemistry, Princeton University, Princeton, NJ, 08544, USA

SO Journal of the American Chemical Society (2003), 125(37), 11168-11169

CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

CC 1-5 (Pharmacology)

Section cross-reference(s): 7, 10

AB MurG is a glycosyltransferase involved in the biosynthesis of bacterial peptidoglycan. It is a potentially important antibiotic target, but no inhibitors of the enzyme have been reported. In general, inhibitors of glycosyltransferases have been difficult to design. Furthermore, no glycosyltransferase inhibitors have been identified through

high-throughput screening, perhaps because appropriate screens for glycosyltransferase inhibition have not been developed. In this manuscript, the authors describe the development of a high-throughput screen for MurG that was used to screen a 50 000 compound library for inhibitors. The screen, which can be generalized to other glycosyltransferases, led to the identification of a family of active-site directed MurG inhibitors. The family of inhibitors contains a five-membered heterocyclic core that appears to function as a diphosphate mimic with respect to the presentation of substituents. The authors discuss the implications of this result and the utility of the screen for identifying inhibitors of other glycosyltransferases.

- ST MurG glycosyltransferase inhibitor identification high throughput screen
 IT Antibacterial agents
 Combinatorial library
 Drug screening
 High throughput screening
 (identification of active-site inhibitors of MurG using a generalizable high-throughput glycosyltransferase screen in relation to antibacterial activity)
- IT Enzyme functional sites
 (inhibitor-binding; identification of active-site inhibitors of MurG using a generalizable high-throughput glycosyltransferase screen in relation to antibacterial activity)
- IT Enzyme kinetics
 (of inhibition; identification of active-site inhibitors of MurG using a generalizable high-throughput glycosyltransferase screen in relation to antibacterial activity)
- IT 608143-47-1
 RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)
 (displacement ligand; identification of active-site inhibitors of MurG using a generalizable high-throughput glycosyltransferase screen in relation to antibacterial activity)
- IT 60976-26-3, MurG glycosyltransferase
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (identification of active-site inhibitors of MurG using a generalizable high-throughput glycosyltransferase screen in relation to antibacterial activity)
- IT 312501-65-8
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (identification of active-site inhibitors of MurG using a generalizable high-throughput glycosyltransferase screen in relation to antibacterial activity)

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Andres, C; Bioorg Med Chem Lett 2000, V10, P715 HCAPLUS
- (2) Bridges, A; Chem Rev 2001, V101, P2541 HCAPLUS
- (3) Bupp, K; J Bacteriol 1993, V175, P1841 HCAPLUS
- (4) Chen, L; Biochemistry 2002, V41, P6824 HCAPLUS
- (5) Cho, J; Biochemistry 1998, V37, P4985 HCAPLUS
- (6) Compain, P; Bioorg Med Chem 2001, V9, P3077 HCAPLUS
- (7) Compain, P; Curr Top Med Chem 2003, V3, P541 HCAPLUS
- (8) El Zoeiby, A; Mol Microbiol 2003, V47, P1 HCAPLUS
- (9) Ha, S; J Am Chem Soc 1999, V121, P8415 HCAPLUS
- (10) Ha, S; Protein Sci 2000, V9, P1045 HCAPLUS
- (11) Helm, J; J Am Chem Soc 2002, V124, P13970 HCAPLUS
- (12) Hertzberg, R; Curr Opin Chem Biol 2000, V4, P445 HCAPLUS
- (13) Hu, Y; Chem Biol 2002, V9, P1287 HCAPLUS
- (14) Hu, Y; Proc Natl Acad Sci U S A 2003, V100, P845 HCAPLUS

- (15) Ikeda, M; Nucleic Acids Res 1990, V18, P4014 HCAPLUS
- (16) Ma, Y; Antimicrob Agents Chemother 2001, V45, P1407 HCAPLUS
- (17) Men, H; J Am Chem Soc 1998, V120, P2484 HCAPLUS
- (18) Mengin-Lecreulx, D; J Bacteriol 1991, V173, P4625 HCAPLUS
- (19) Qian, X; Carbohydr Chem Biol 2000, V3, P293 HCAPLUS
- (20) Salmond, G; J Bacteriol 1980, V144, P438 HCAPLUS
- (21) Saotome, C; Chem Biol 2001, V8, P1061 HCAPLUS
- (22) Seltmann, G; The Bacterial Cell Wall 2002
- (23) Sim, M; Bioorg Med Chem Lett 2002, V12, P697 HCAPLUS
- (24) Walsh, C; Antibiotics: Actions, Origins, Resistance 2003
- (25) Wang, R; Bioorg Med Chem 1997, V5, P661 HCAPLUS
- (26) Wong, K; Adv Exp Med Biol 1998, V456, P197 HCAPLUS
- (27) Zhang, Z; Annu Rev Pharmacol Toxicol 2002, V42, P209 HCAPLUS

IT 608143-47-1

RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);


BIOL (Biological study); USES (Uses)

(displacement ligand; identification of active-site inhibitors of MurG using a generalizable high-throughput glycosyltransferase screen in relation to antibacterial activity)

RN 608143-47-1 HCAPLUS

CN Uridine 5'-(trihydrogen diphosphate), P'-[2-deoxy-2-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)carbonyl]amino]acetyl]amino]- α -D-glucopyranosyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L59 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:367026 HCAPLUS

DN 125:50470

ED Entered STN: 25 Jun 1996

TI Molecular cloning of the Golgi apparatus **uridine diphosphate-N-acetylglucosamine** transporter from *Kluyveromyces lactis*


AU Abeijon, Claudia; Robbins, Phillips W.; Hirschberg, Carlos B.

CS Dep. Biochem. Mol. Biol., Univ. Massachusetts Med. Cent., Worcester, MA, 01655, USA

- SO Proceedings of the National Academy of Sciences of the United States of America (1996), 93(12), 5963-5968
CODEN: PNASA6; ISSN: 0027-8424
- PB National Academy of Sciences
- DT Journal
- LA English
- CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 10
- AB The mannan chains of *Kluyveromyces lactis* mannoproteins are similar to those of *Saccharomyces cerevisiae* except that they lack mannose phosphate and have terminal $\alpha 1 \rightarrow 2$ -linked N- **acetylglucosamine**. The biosynthesis of these chains probably occurs in the human of the Golgi apparatus, by analogy to *S. cerevisiae*. The sugar donors, GDP-mannose and **UDP-GlcNAc**, must first be transported from the cytosol, their site of synthesis, via specific Golgi membrane transporters into the lumen where they are substrates in the biosynthesis of these mannoproteins. A mutant of *K. lactis*, *mnn2-2*, that lacks terminal N- **acetylglucosamine** in its mannan chains in vivo, has recently been characterized and shown to have a specific defect in transport of **UDP-GlcNAc** into the lumen of Golgi vesicles in vitro. We have now cloned the gene encoding the *K. lactis* Golgi membrane **UDP-GlcNAc** transporter by complementation of the *mnn2-2* mutation. The *mnn2-2* mutant was transformed with a genomic library from wild-type *K. lactis* in a pKD1-derived vector; transformants were isolated and phenotypic correction was monitored following cell surface labeling with **fluorescein isothiocyanate** conjugated to *Griffonia simplicifolia* II lectin, which binds terminal N-**acetylglucosamine**, and a fluorescent activated cell sorter. A 2.4-kb DNA fragment was found to restore the wild-type lectin binding phenotype. Upon loss of the plasmid containing this fragment, reversion to the mutant phenotype occurred. The above fragment contained an open reading frame for a multitransmembrane spanning protein of 328 amino acids. The protein contains a leucine zipper motif and has high homol. to predicted proteins from *S. cerevisiae* and *C. elegans*. In an assay in vitro, Golgi vesicles isolated from the transformant had regained their ability to transport **UDP-GlcNAc**. Taken together, the above results strongly suggest that the cloned gene encodes the golgi **UDP-GlcNAc** transporter of *K. lactis*.
- ST *Kluyveromyces* Golgi **uridine diphosphate acetylglucosamine** transporter; **uridine diphosphate acetylglucosamine** transporter gene sequence
- IT Cell membrane
(2.4-kb DNA fragment which was found to restore the wild-type lectin binding phenotype to *Kluyveromyces lactis* *mnn2-2* mutant contained an open reading frame for a multitransmembrane spanning protein of 328 amino acids)
- IT Complementation, genetic
(gene encoding the *Kluyveromyces lactis* Golgi membrane **UDP-GlcNAc** transporter has been cloned by complementation of the *mnn2-2* mutation)
- IT Mutation
(*mnn2-2*; gene encoding the *Kluyveromyces lactis* Golgi membrane **UDP-GlcNAc** transporter has been cloned by complementation of the *mnn2-2* mutation)
- IT Golgi apparatus
Kluyveromyces lactis
Molecular cloning
(mol. cloning of the Golgi apparatus **uridine diphosphate -N-acetylglucosamine** transporter from *Kluyveromyces lactis*)
- IT Protein sequences

- (of the Golgi apparatus **uridine diphosphate-N-acetylglucosamine** transporter from *Kluyveromyces lactis*)
- IT Deoxyribonucleic acid sequences
(of the Golgi apparatus **uridine diphosphate-N-acetylglucosamine** transporter gene from *Kluyveromyces lactis*)
- IT Plasmid and Episome
(upon loss of the plasmid containing the 2.4-kb DNA fragment which was found to restore the wild-type lectin binding phenotype to *Kluyveromyces lactis* mnn2-2 mutant, reversion to the mutant phenotype occurred)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(UDP-N-**acetylglucosamine**-transporting, mol. cloning of the Golgi apparatus **uridine diphosphate-N-acetylglucosamine** transporter from *Kluyveromyces lactis*)
- IT Conformation and Conformers
(leucine zipper, protein which was found to restore the wild-type lectin binding phenotype to *Kluyveromyces lactis* mnn2-2 mutant contains a leucine zipper motif and has high homol. to predicted proteins from *S. cerevisiae* and *C. elegans*)
- IT 178235-60-4
RL: PRP (Properties)
(amino acid sequence; mol. cloning of the Golgi apparatus **uridine diphosphate-N-acetylglucosamine** transporter from *Kluyveromyces lactis*)
- IT 528-04-1, **Uridine diphosphate-N-acetylglucosamine**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(mol. cloning of the Golgi apparatus **uridine diphosphate-N-acetylglucosamine** transporter from *Kluyveromyces lactis*)
- IT 177526-16-8, GenBank U48413
RL: PRP (Properties)
(nucleotide sequence; mol. cloning of the Golgi apparatus **uridine diphosphate-N-acetylglucosamine** transporter from *Kluyveromyces lactis*)
- IT 528-04-1, **Uridine diphosphate-N-acetylglucosamine**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(mol. cloning of the Golgi apparatus **uridine diphosphate-N-acetylglucosamine** transporter from *Kluyveromyces lactis*)
- RN 528-04-1 HCAPLUS
- CN Uridine 5'-(trihydrogen diphosphate), P'-[2-(acetylamino)-2-deoxy- α -D-glucopyranosyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L59 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1988:525962 HCAPLUS
 DN 109:125962
 ED Entered STN: 14 Oct 1988
 TI Metabolism of D-[U-14C]glucosamine in seedlings of *Calluna vulgaris* (L.)
 Hull
 AU Piro, G.; Perotto, S.; Bonfante-Fasolo, P.; Dalessandro, G.
 CS Dip. Biol., Univ. Stud. Lecce, Lecce, I-73100, Italy
 SO Journal of Plant Physiology (1988), 132(6), 695-701
 CODEN: JPPHEY; ISSN: 0176-1617
 DT Journal
 LA English
 CC 11-2 (Plant Biochemistry)
 AB Exogenous D-[U-14C]glucosamine was taken up by roots of *C. vulgaris* seedlings, translocated throughout the plant and metabolized to N-acetyl-D-glucosamine, N-acetyl-D-glucosamine 6-phosphate, N-acetyl-D-glucosamine 1-phosphate, UDP-N-acetyl-D-glucosamine and UDP-N-acetyl-D-galactosamine. The N-acetyl-D-hexosamine nucleosides acted as glycosyl donors of polymers containing N-acetyl-D-glucosamine and N-acetyl-D-galactosamine residues. The presence of N-acetyl-D-glucosamine residues at the surface of hair roots was shown by using wheat germ agglutinin linked to fluorescein isothiocyanate or colloidal gold as specific probes.
 ST *Calluna* glucosamine metab
 IT Root
 (acetylglucosamine residues at surface of, localization of)
 IT Glycoproteins, biological studies
 RL: BIOL (Biological study)
 (glucosamine incorporation in, in *Calluna vulgaris* seedlings)
 IT *Calluna vulgaris*
 (glucosamine metabolism in seedlings of)
 IT Translocation
 (of glucosamine in *Calluna vulgaris* seedlings)
 IT 528-04-1, UDP-N-acetyl-D-glucosamine
 1746-32-3, N-Acetyl-D-glucosamine 6-phosphate
 6866-69-9 7277-98-7, UDP-N-acetyl
 -D-galactosamine 7512-17-6, N-Acetyl-D-glucosamine
 RL: FORM (Formation, nonpreparative)
 (formation of, from glucosamine, in *Calluna vulgaris* seedlings)
 IT 3416-24-8, D-Glucosamine

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of, in *Calluna vulgaris* seedlings)

IT 528-04-1, UDP-N-acetyl-D-glucosamine
1746-32-3, N-Acetyl-D-glucosamine 6-phosphate


6866-69-9 7277-98-7, UDP-N-acetyl
-D-galactosamine 7512-17-6, N-Acetyl-D-
glucosamine

RL: FORM (Formation, nonpreparative)
(formation of, from glucosamine, in *Calluna vulgaris*
seedlings)

RN 528-04-1 HCAPLUS

CN Uridine 5'-(trihydrogen diphosphate), P'-[2-(acetyl-amino)-2-deoxy- α -
D-glucopyranosyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 1746-32-3 HCAPLUS

CN D-Glucose, 2-(acetyl-amino)-2-deoxy-, 6-(dihydrogen phosphate) (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 6866-69-9 HCAPLUS

CN D-Glucopyranose, 2-(acetyl-amino)-2-deoxy-, 1-(dihydrogen phosphate) (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 7277-98-7 HCAPLUS

CN Uridine 5'-(trihydrogen diphosphate), P'-[2-(acetylamino)-2-deoxy- α -D-galactopyranosyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 7512-17-6 HCAPLUS

CN D-Glucose, 2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 15:03:15 ON 18 OCT 2005)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 15:03:41 ON 18 OCT 2005

L1 1 S US20050142629/PN OR US2003-784335#/AP, PRN
E KAHNE D/AU
L2 117 S E3-E7
E KAHNE S/AU
L3 8 S E4, E5
E WALKER S/AU
L4 210 S E3

L5 20 S E17
E WALKER SUE/AU
L6 48 S E21
SEL RN L1

FILE 'REGISTRY' ENTERED AT 15:05:45 ON 18 OCT 2005

L7 48 S E1-E48
L8 4 S L7 AND (OC5-C6-C6 OR OC4-OC5-C6-C6)/ES
L9 2 S L8 AND OC5/ES
L10 1 S L9 AND NCNC3/ES
L11 75563 S (OC5-C6-C6 OR OC4-OC5-C6-C6)/ES
L12 1637 S L11 AND OC5/ES
L13 103 S L12 AND (OC4 AND NCNC3)/ES
L14 91 S L13 AND P/ELS
L15 28 S L14 AND 8/NR
L16 17 S L15 NOT S/ELS
L17 1 S L16 AND C38H38N4O23P2
L18 2 S L8 AND OC4-OC5-C6-C6-C6/ES NOT L9
L19 1 S L18 NOT N/ELS
L20 1 S 58-98-0
E N-ACT5EYLGLUCOSAMINE/CN
E N-ACETYLGLUCOSAMINE/CN
L21 1 S E3
E C38H38N4O23P2/MF

FILE 'HCAOLD' ENTERED AT 15:16:10 ON 18 OCT 2005

L22 0 S L17

FILE 'HCAPLUS' ENTERED AT 15:16:14 ON 18 OCT 2005

L23 2 S L17
L24 0 S L19 AND L20 AND L21
L25 6310 S L19
L26 25115 S FLUORESCEIN?
L27 25589 S L25,L26
L28 2084 S L20
L29 16687 S UDP OR URID? (L) DIHYDROGEN (L) ?PHOSPH?
L30 16657 S UDP OR URID? (L) ?PHOSPH? (L) GLUCORON?
L31 4962 S URID? (L) DIPHOSPH?
L32 40 S L27 AND L28-L31
L33 5969 S L21
L34 25484 S ?ACETYLGLUCOSAMIN? OR ?ACETY? (L) ?GLUCOSAMIN?
L35 9 S L32 AND L33,L34

FILE 'REGISTRY' ENTERED AT 15:25:37 ON 18 OCT 2005

L36 1 S 528-04-1

FILE 'HCAPLUS' ENTERED AT 15:25:47 ON 18 OCT 2005

L37 1276 S L36
L38 7 S L37 AND L27
L39 1 S L38 NOT L35
SEL DN AN L35 2 4 8 9
L40 4 S E1-E12 AND L35
L41 4 S L37 AND L40
L42 5 S L23,L41
L43 2 S L1-L6 AND L42
L44 5 S L42,L43
L45 2 S L44 AND GLCNAC
L46 5 S L44,L45

FILE 'USPATFULL, USPAT2' ENTERED AT 15:29:27 ON 18 OCT 2005

L47 1 S L17

FILE 'USPATFULL, USPAT2' ENTERED AT 15:29:46 ON 18 OCT 2005

FILE 'HCAPLUS' ENTERED AT 15:29:53 ON 18 OCT 2005
SEL RN L46

FILE 'REGISTRY' ENTERED AT 15:30:24 ON 18 OCT 2005

L48 103 S E13-E115
L49 4 S L48 AND OC4-OC5-C6-C6-C6/ES
L50 1 S L48 AND L36
L51 4 S L48 AND L10,L17,L19,L20,L21
L52 7 S L49-L51
L53 6 S L48 AND (NCNC3 AND OC4)/ES NOT L52
L54 3 S L53 NOT (THYMIDINE OR C6/ES)
L55 10 S L52,L54
L56 90 S L48 NOT L49-L55
L57 3 S L56 AND (C8H16NO9P OR C20H16N2O4)
L58 13 S L55,L57

FILE 'HCAPLUS' ENTERED AT 15:36:01 ON 18 OCT 2005

L59 5 S L58 AND L46

=>